Outcome of poor initial TIMI flow in patients presenting with acute coronary syndrome

References

• Rakowski T, Dudek D, Dziewierz A, et al. Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. EuroIntervention. 2013;8:1307–1314.
   PubMed Web of Science ®Google Scholar
• Brener SJ, Mehran R, Brodie BR, et al. Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). Am J Cardiol. 2011;108:918–923.
   PubMed Web of Science ®Google Scholar
• Rakowski T, Siudak Z, Dziewierz A, et al. Impact of infarct related artery patency after early abciximab administration on one-year mortality in patients with ST-segment elevation myocardial infarction (data from the EUROTRANSFER Registry). Kardiol Pol. 2012;70:215–221.
   PubMed Web of Science ®Google Scholar
• Bongard V, Puel J, Savary D, et al. Predictors of infarct artery patency after prehospital thrombolysis: the multicentre, prospective, observational OPTIMAL study. Heart. 2009;95:799–806.
   PubMed Web of Science ®Google Scholar
• Bailleul C, Puymirat E, Aissaoui N, et al. Factors associated with infarct-related artery patency before primary percutaneous coronary intervention for st-elevation myocardial infarction (from the FAST-MI 2010 registry). Am J Cardiol. 2016;117:17–21.
   PubMed Web of Science ®Google Scholar
• Mosseri M, Miller H, Tamari I, et al. The titanium-NO stent: results of a multicenter registry. Eurointervention. 2006;2:192–196.
   PubMedGoogle Scholar
• Karjalainen PP, Ylitalo A, Airaksinen KEJ, et al. Five-year clinical outcome of titanium nitride-oxide-coated bioactive stent implantation in a real world population: a comparison with paclitaxel-eluting stents: The PORI registry. J Interv Cardiol. 2011;24:1–8.
   PubMed Web of Science ®Google Scholar
• Tuomainen PO, Ylitalo A, Niemelä M, et al. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial. Int J Cardiol. 2013;168:1214–1219.
   PubMed Web of Science ®Google Scholar
• Karjalainen PP, Niemelä M, Airaksinen JK, et al. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial. EuroIntervention. 2012;8:306–315.
   PubMed Web of Science ®Google Scholar
• Romppanen H, Nammas W, Kervinen K, et al. Karjalainen PP, Stent-oriented versus patient-oriented outcome in patients undergoing early percutaneous coronary intervention for acute coronary syndrome: 2-year report from the BASE-ACS trial. Ann Med. 2013;45:488–493.
   PubMed Web of Science ®Google Scholar
• Karjalainen PP, Niemelä M, Pietilä M, et al. Clinical outcome of titanium-nitride-oxide-coated bioactive stents versus everolimus-eluting stents in acute coronary syndrome: 4-year report of the BASE-ACS trial. Scand Cardiovasc J. 2016;50:218–223.
   PubMed Web of Science ®Google Scholar
• Karjalainen PP, Nammas W, Ylitalo A, et al. Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial. Int J Cardiol. 2016;222:275–280.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351.
   PubMed Web of Science ®Google Scholar
• Sahin DY, Gür M, Elbasan Z, et al. Predictors of preinterventional patency of infarct-related artery in patients with ST-segment elevation myocardial infarction: importance of neutrophil to lymphocyte ratio and uric acid level. Exp Clin Cardiol. 2013;18:e77–e81.
   PubMedGoogle Scholar
• Acet H, Ertaş F, Akıl MA, et al. Novel predictors of infarct-related artery patency for ST-segment elevation myocardial infarction: platelet-to-lymphocyte ratio, uric acid, and neutrophil-to-lymphocyte ratio. Anatol J Cardiol. 2015;15:648–656.
   PubMed Web of Science ®Google Scholar
• Yayla Ç, Akboğa MK, Canpolat U, et al. Platelet to Lymphocyte ratio can be a predictor of infarct-related artery patency in patients with ST-segment elevation myocardial infarction. Angiology. 2015;66:831–836.
   PubMed Web of Science ®Google Scholar
• Maden O, Kacmaz F, Selcuk MT, et al. Relationship of admission haematological indices with infarct-related artery patency in patients with acute ST-segment elevation myocardial infarction treated with primary angioplasty. Coron Artery Dis. 2007;18:639–644.
   PubMed Web of Science ®Google Scholar
• Keleş T, Yeter E, Durmaz T, et al. Relation of homocysteine levels with patency and flow rate of infarct-related artery in patients receiving fibrinolytic therapy. Anadolu Kardiyol Derg. 2010;10:410–415.
   PubMedGoogle Scholar
• Misumida N, Kobayashi A, Saeed M, et al. Association between preinfarction angina and angiographic findings in non-ST-segment elevation myocardial infarction. Clin Cardiol. 2015;38:535–541.
   PubMed Web of Science ®Google Scholar
• Goto K, Lansky AJ, Nikolsky E, et al. Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. JACC Cardiovasc Interv. 2011;4:769–777.
   PubMed Web of Science ®Google Scholar
• Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50:573–583.
   PubMed Web of Science ®Google Scholar
• Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation. 2006;113:414–419.
   PubMed Web of Science ®Google Scholar
• Hassan AK, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J. 2010;31:1172–1180.
   PubMed Web of Science ®Google Scholar